Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

The population-attributable fraction for time-dependent exposures using dynamic prediction and landmarking.

von Cube M, Schumacher M, Putter H, Timsit JF, van de Velde C, Wolkewitz M.

Biom J. 2019 Jun 19. doi: 10.1002/bimj.201800252. [Epub ahead of print]

PMID:
31216103
2.

The impact of hospital-acquired infections on the patient-level reimbursement-cost relationship in a DRG-based hospital payment system.

Kaier K, Wolkewitz M, Hehn P, Mutters NT, Heister T.

Int J Health Econ Manag. 2019 Jun 5. doi: 10.1007/s10754-019-09267-w. [Epub ahead of print]

PMID:
31165960
3.

The population-attributable fraction for time-dependent exposures and competing risks-A discussion on estimands.

von Cube M, Schumacher M, Bailly S, Timsit JF, Lepape A, Savey A, Machut A, Wolkewitz M.

Stat Med. 2019 Jun 4. doi: 10.1002/sim.8208. [Epub ahead of print]

PMID:
31162706
4.

Estimands to quantify prolonged hospital stay associated with nosocomial infections.

Wolkewitz M, Schumacher M, Rücker G, Harbarth S, Beyersmann J.

BMC Med Res Methodol. 2019 May 31;19(1):111. doi: 10.1186/s12874-019-0752-6.

5.

Analyzing the impact of duration of ventilation, hospitalization, and ventilation episodes on the risk of pneumonia.

Wolkewitz M, Palomar-Martinez M, Alvarez-Lerma F, Olaechea-Astigarraga P, Schumacher M.

Infect Control Hosp Epidemiol. 2019 Mar;40(3):301-306. doi: 10.1017/ice.2018.360. Epub 2019 Feb 18.

PMID:
30773159
6.

RE: "RISK-SET MATCHING TO ASSESS THE IMPACT OF HOSPITAL-ACQUIRED BLOODSTREAM INFECTIONS".

Ohneberg K, Wolkewitz M, Schumacher M.

Am J Epidemiol. 2019 Jun 1;188(6):1192-1193. doi: 10.1093/aje/kwz035. No abstract available.

PMID:
30759196
7.

Measuring the financial burden of resistance: What should be compared?

Kaier K, Mutters NT, Wolkewitz M.

Clin Infect Dis. 2019 Feb 11. doi: 10.1093/cid/ciz096. [Epub ahead of print] No abstract available.

PMID:
30753374
8.

Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile: a competing risks analysis provides a full picture of possible treatment effects.

von Cube MK, Schumacher M, Wolkewitz M; COMBACTE-MAGNET Consortium.

Gut. 2018 Dec 28. pii: gutjnl-2018-317839. doi: 10.1136/gutjnl-2018-317839. [Epub ahead of print] No abstract available.

PMID:
30593454
9.

Investigating the impact of early valve surgery on survival in Staphylococcus aureus infective endocarditis using a marginal structural model approach - results of a large prospectively evaluated cohort.

Rieg S, von Cube M, Kaasch A, Bonaventura B, Bothe W, Wolkewitz M, Peyerl-Hoffmann G, Deppe AC, Wahlers T, Beyersdorf F, Seifert H, Kern WV.

Clin Infect Dis. 2018 Oct 22. doi: 10.1093/cid/ciy908. [Epub ahead of print]

PMID:
30346527
10.

Estimation of adjusted expected excess length-of-stay associated with ventilation-acquired pneumonia in intensive care: A multistate approach accounting for time-dependent mechanical ventilation.

Bluhmki T, Allignol A, Ruckly S, Timsit JF, Wolkewitz M, Beyersmann J.

Biom J. 2018 Nov;60(6):1135-1150. doi: 10.1002/bimj.201700242. Epub 2018 Sep 9.

PMID:
30198195
11.

Improving nested case-control studies to conduct a full competing-risks analysis for nosocomial infections.

Hazard D, Schumacher M, Palomar-Martinez M, Alvarez-Lerma F, Olaechea-Astigarraga P, Wolkewitz M.

Infect Control Hosp Epidemiol. 2018 Oct;39(10):1196-1201. doi: 10.1017/ice.2018.186. Epub 2018 Aug 30.

PMID:
30157989
12.

Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.

de Kraker MEA, Sommer H, de Velde F, Gravestock I, Weiss E, McAleenan A, Nikolakopoulos S, Amit O, Ashton T, Beyersmann J, Held L, Lovering AM, MacGowan AP, Mouton JW, Timsit JF, Wilson D, Wolkewitz M, Bettiol E, Dane A, Harbarth S; COMBACTE-NET Consortium.

Clin Infect Dis. 2018 Nov 28;67(12):1922-1931. doi: 10.1093/cid/ciy516.

13.

Effectiveness of a hospital-wide infection control programme on the incidence of healthcare-associated infections and associated severe sepsis and septic shock: a prospective interventional study.

Hagel S, Ludewig K, Pletz MW, Frosinski J, Moeser A, Wolkewitz M, Gastmeier P, Harbarth S, Brunkhorst FM, Kesselmeier M, Scherag A.

Clin Microbiol Infect. 2019 Apr;25(4):462-468. doi: 10.1016/j.cmi.2018.07.010. Epub 2018 Jul 21.

14.

Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes.

Poguntke I, Schumacher M, Beyersmann J, Wolkewitz M.

BMC Med Res Methodol. 2018 Jul 16;18(1):79. doi: 10.1186/s12874-018-0535-5.

15.

The Impact of Early Adequate Treatment on Extubation and Discharge Alive of Patients With Pseudomonas aeruginosa-Related Ventilator-Associated Pneumonia.

Sommer H, Timsit JF, von Cube M, Schumacher M, Darmon M, Schwebel C, Ruckly S, Wolkewitz M; COMBACTE-MAGNET Consortium.

Crit Care Med. 2018 Oct;46(10):1643-1648. doi: 10.1097/CCM.0000000000003305.

PMID:
29985212
16.

Bias due to censoring of deaths when calculating extra length of stay for patients acquiring a hospital infection.

Rahman S, von Cube M, Schumacher M, Wolkewitz M.

BMC Med Res Methodol. 2018 May 30;18(1):49. doi: 10.1186/s12874-018-0500-3.

17.

Abdominal aortic aneurysm neck remodeling after Anaconda stent graft implantation.

Vukovic E, Czerny M, Beyersdorf F, Wolkewitz M, Berezowski M, Siepe M, Blanke P, Rylski B.

J Vasc Surg. 2018 Nov;68(5):1354-1359.e2. doi: 10.1016/j.jvs.2018.02.041. Epub 2018 May 24.

PMID:
29804739
18.

Methodological challenges in using point-prevalence versus cohort data in risk factor analyses of nosocomial infections.

Wolkewitz M, Mandel M, Palomar-Martinez M, Alvarez-Lerma F, Olaechea-Astigarraga P, Schumacher M.

Ann Epidemiol. 2018 Jul;28(7):475-480.e1. doi: 10.1016/j.annepidem.2018.03.017. Epub 2018 Apr 3.

PMID:
29661679
19.

Estimating the attributable costs of hospital-acquired infections requires a distinct categorization of cases based on time of infection.

Kaier K, Wolkewitz M, Heister T.

Am J Infect Control. 2018 Jun;46(6):729. doi: 10.1016/j.ajic.2018.02.014. Epub 2018 Apr 11. No abstract available.

PMID:
29655667
20.

Determining the Attributable Costs of Clostridium difficile Infections When Exposure Time Is Lacking: Be Wary of "Conditioning on the Future".

Heister T, Wolkewitz M, Kaier K.

Infect Control Hosp Epidemiol. 2018 Jun;39(6):759-760. doi: 10.1017/ice.2018.42. Epub 2018 Mar 28. No abstract available.

PMID:
29587890
21.

Risk prediction for Staphylococcus aureus surgical site infection following cardiothoracic surgery; A secondary analysis of the V710-P003 trial.

Paling FP, Olsen K, Ohneberg K, Wolkewitz M, Fowler VG Jr, DiNubile MJ, Jafri HS, Sifakis F, Bonten MJM, Harbarth SJ, Kluytmans JAJW.

PLoS One. 2018 Mar 21;13(3):e0193445. doi: 10.1371/journal.pone.0193445. eCollection 2018.

22.

Relative risk and population-attributable fraction of ICU death caused by susceptible and resistant Pseudomonas aeruginosa ventilator-associated pneumonia: a competing risks approach to investigate the OUTCOMEREA database.

von Cube MK, Timsit JF, Sommer H, Darmon M, Schwebel C, Bailly S, Souweine B, Wolkewitz M.

Intensive Care Med. 2018 Jul;44(7):1177-1179. doi: 10.1007/s00134-018-5109-9. Epub 2018 Mar 16. No abstract available.

PMID:
29549409
23.

Use of prevalence data to study sepsis incidence and mortality in intensive care units.

Doerken S, Mandel M, Zingg W, Wolkewitz M.

Lancet Infect Dis. 2018 Mar;18(3):252. doi: 10.1016/S1473-3099(18)30081-1. No abstract available.

PMID:
29485090
24.

Estimating the additional costs of surgical site infections: length bias, time-dependent bias, and conditioning on the future.

Heister T, Wolkewitz M, Kaier K.

J Hosp Infect. 2018 May;99(1):103-104. doi: 10.1016/j.jhin.2018.02.012. Epub 2018 Feb 16. No abstract available.

PMID:
29458064
25.

Prevention of hospital infections by intervention and training (PROHIBIT): results of a pan-European cluster-randomized multicentre study to reduce central venous catheter-related bloodstream infections.

van der Kooi T, Sax H, Pittet D, van Dissel J, van Benthem B, Walder B, Cartier V, Clack L, de Greeff S, Wolkewitz M, Hieke S, Boshuizen H, van de Kassteele J, Van den Abeele A, Boo TW, Diab-Elschahawi M, Dumpis U, Ghita C, FitzGerald S, Lejko T, Leleu K, Martinez MP, Paniara O, Patyi M, Schab P, Raglio A, Szilágyi E, Ziętkiewicz M, Wu AW, Grundmann H, Zingg W; PROHIBIT consortium.

Intensive Care Med. 2018 Jan;44(1):48-60. doi: 10.1007/s00134-017-5007-6. Epub 2017 Dec 16.

PMID:
29248964
26.

Analyzing the impact of depth of response on survival in patients with metastatic non-small-cell lung cancer.

Weber S, Wolkewitz M, Schumacher M.

Ann Oncol. 2018 Jan 1;29(1):282-283. doi: 10.1093/annonc/mdx558. No abstract available.

PMID:
29045521
27.

Rationale and design of ASPIRE-ICU: a prospective cohort study on the incidence and predictors of Staphylococcus aureus and Pseudomonas aeruginosa pneumonia in the ICU.

Paling FP, Troeman DPR, Wolkewitz M, Kalyani R, Prins DR, Weber S, Lammens C, Timbermont L, Goossens H, Malhotra-Kumar S, Sifakis F, Bonten MJM, Kluytmans JAJW.

BMC Infect Dis. 2017 Sep 25;17(1):643. doi: 10.1186/s12879-017-2739-4.

28.

Basic parametric analysis for a multi-state model in hospital epidemiology.

von Cube M, Schumacher M, Wolkewitz M.

BMC Med Res Methodol. 2017 Jul 20;17(1):111. doi: 10.1186/s12874-017-0379-4.

29.

Multistate Modeling to Analyze Nosocomial Infection Data: An Introduction and Demonstration.

Wolkewitz M, von Cube M, Schumacher M.

Infect Control Hosp Epidemiol. 2017 Aug;38(8):953-959. doi: 10.1017/ice.2017.107. Epub 2017 Jun 21.

PMID:
28633679
30.

The time-dependent "cure-death" model investigating two equally important endpoints simultaneously in trials treating high-risk patients with resistant pathogens.

Sommer H, Wolkewitz M, Schumacher M; COMBACTE-NET consortium.

Pharm Stat. 2017 Jul;16(4):267-279. doi: 10.1002/pst.1809. Epub 2017 Jun 9.

PMID:
28598541
31.

Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study.

Weberpals J, Jansen L, Haefeli WE, Hoffmeister M, Wolkewitz M, Herk-Sukel MPPV, Vissers PAJ, Brenner H.

Sci Rep. 2017 Jun 6;7(1):2911. doi: 10.1038/s41598-017-02913-8.

32.

Competing risks need to be considered in survival analysis models for cardiovascular outcomes.

Huebner M, Wolkewitz M, Enriquez-Sarano M, Schumacher M.

J Thorac Cardiovasc Surg. 2017 Jun;153(6):1427-1431. doi: 10.1016/j.jtcvs.2016.12.039. Epub 2017 Feb 3. No abstract available.

33.

Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net.

Timsit JF, de Kraker MEA, Sommer H, Weiss E, Bettiol E, Wolkewitz M, Nikolakopoulos S, Wilson D, Harbarth S; COMBACTE-NET consortium.

Intensive Care Med. 2017 Jul;43(7):1002-1012. doi: 10.1007/s00134-017-4802-4. Epub 2017 May 2.

34.

P. aeruginosa colonization at ICU admission as a risk factor for developing P. aeruginosa ICU pneumonia.

Paling FP, Wolkewitz M, Depuydt P, de Bus L, Sifakis F, Bonten MJM, Kluytmans JAJW.

Antimicrob Resist Infect Control. 2017 Apr 20;6:38. doi: 10.1186/s13756-017-0197-9. eCollection 2017.

35.

Bezlotoxumab and Recurrent Clostridium difficile Infection.

Sommer H, Timsit JF, Wolkewitz M; COMBACTE-NET Consortium.

N Engl J Med. 2017 Apr 20;376(16):1594. doi: 10.1056/NEJMc1702531. No abstract available.

PMID:
28423299
36.

Changes in Rates of Ventilator-Associated Pneumonia.

Wolkewitz M, Rücker G, Schumacher M.

JAMA. 2017 Apr 18;317(15):1580-1581. doi: 10.1001/jama.2017.2411. No abstract available.

PMID:
28418475
37.

Correction: Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.

Wolkewitz M, Schumacher M.

PLoS One. 2017 Apr 6;12(4):e0175660. doi: 10.1371/journal.pone.0175660. eCollection 2017.

38.

Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: Results from a population-based study.

Jansen L, Weberpals J, Kuiper JG, Vissers PAJ, Wolkewitz M, Hoffmeister M, Brenner H.

Int J Cancer. 2017 Jul 1;141(1):62-71. doi: 10.1002/ijc.30717.

39.

Fate of the dissected aortic arch after ascending replacement in type A aortic dissection†.

Rylski B, Hahn N, Beyersdorf F, Kondov S, Wolkewitz M, Blanke P, Plonek T, Czerny M, Siepe M.

Eur J Cardiothorac Surg. 2017 Jun 1;51(6):1127-1134. doi: 10.1093/ejcts/ezx062.

PMID:
28369453
40.

Landmark prediction of nosocomial infection risk to disentangle short- and long-stay patients.

Wolkewitz M, Zortel M, Palomar-Martinez M, Alvarez-Lerma F, Olaechea-Astigarraga P, Schumacher M.

J Hosp Infect. 2017 May;96(1):81-84. doi: 10.1016/j.jhin.2017.01.017. Epub 2017 Feb 4.

PMID:
28285741
41.

Survival biases lead to flawed conclusions in observational treatment studies of influenza patients.

Wolkewitz M, Schumacher M.

J Clin Epidemiol. 2017 Apr;84:121-129. doi: 10.1016/j.jclinepi.2017.01.008. Epub 2017 Feb 7.

PMID:
28188897
42.

Time series models of environmental exposures: Good predictions or good understanding.

Barnett AG, Stephen D, Huang C, Wolkewitz M.

Environ Res. 2017 Apr;154:222-225. doi: 10.1016/j.envres.2017.01.007. Epub 2017 Jan 17.

PMID:
28104512
43.

RE: "COMPARISON OF STATISTICAL APPROACHES FOR DEALING WITH IMMORTAL TIME BIAS IN DRUG EFFECTIVENESS STUDIES".

Wolkewitz M, Beyersmann J, Ohneberg K, Schumacher M.

Am J Epidemiol. 2016 Dec 1;184(11):856-858. Epub 2016 Nov 16. No abstract available.

PMID:
27852601
44.

Estimating the burden of nosocomial infections: Time dependency and cost clustering should be taken into account.

Heister T, Kaier K, Wolkewitz M.

Am J Infect Control. 2017 Jan 1;45(1):94-95. doi: 10.1016/j.ajic.2016.07.030. Epub 2016 Nov 9. No abstract available.

PMID:
27836389
45.

A case-cohort approach for multi-state models in hospital epidemiology.

von Cube M, Schumacher M, Palomar-Martinez M, Olaechea-Astigarraga P, Alvarez-Lerma F, Wolkewitz M.

Stat Med. 2017 Feb 10;36(3):481-495. doi: 10.1002/sim.7146. Epub 2016 Oct 24.

PMID:
27774627
46.

Staphylococcus aureus colonization at ICU admission as a risk factor for developing S. aureus ICU pneumonia.

Paling FP, Wolkewitz M, Bode LGM, Klein Klouwenberg PMC, Ong DSY, Depuydt P, de Bus L, Sifakis F, Bonten MJM, Kluytmans JAJW.

Clin Microbiol Infect. 2017 Jan;23(1):49.e9-49.e14. doi: 10.1016/j.cmi.2016.09.022. Epub 2016 Sep 29.

47.

Multiple time scales in modeling the incidence of infections acquired in intensive care units.

Wolkewitz M, Cooper BS, Palomar-Martinez M, Alvarez-Lerma F, Olaechea-Astigarraga P, Barnett AG, Schumacher M.

BMC Med Res Methodol. 2016 Sep 1;16(1):116. doi: 10.1186/s12874-016-0199-y.

48.

Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.

Wolkewitz M, Schumacher M.

PLoS One. 2016 Sep 1;11(9):e0160430. doi: 10.1371/journal.pone.0160430. eCollection 2016. Erratum in: PLoS One. 2017 Apr 6;12 (4):e0175660.

49.

Necessity of a Competing Risk Approach in Risk Factor Analysis of Central Line-Associated Bloodstream Infection.

Weber S, von Cube M, Sommer H, Wolkewitz M.

Infect Control Hosp Epidemiol. 2016 Oct;37(10):1255-7. doi: 10.1017/ice.2016.166. Epub 2016 Aug 17. No abstract available.

PMID:
27530258
50.

Accounting for Competing Events in Multivariate Analyses of Hospital-Acquired Infection Risk Factors.

Wolkewitz M.

Infect Control Hosp Epidemiol. 2016 Sep;37(9):1122-4. doi: 10.1017/ice.2016.162. Epub 2016 Jul 25. No abstract available.

PMID:
27452870

Supplemental Content

Loading ...
Support Center